A Novartis heart drug lowered lipoprotein(a), a genetic heart risk factor, but failed to reduce heart attacks, strokes or ...
Heart disease and chronic kidney disease can accelerate one another, but new guidelines say simple screening and early ...
New ESC guidelines highlight the close connection between heart and kidney health, urging cardiovascular patients to undergo ...
A common liver condition thought to be harmless could be dramatically increasing the risk of heart disease, kidney failure ...
Liz covers cardiovascular and metabolic disease, asking why we’re not doing better or even losing ground against the world’s leading killer. Send tips on Signal at LizC.22. Leading medical ...
Researchers found that urolithin A improved relaxation in engineered human heart tissue and reduced several hallmarks of ...
A narrative review finds insomnia is a consistent, dose-dependent cardiovascular risk factor, but trials have not shown that ...
Shares of Novartis fell more than 3% on Monday after its cholesterol drug failed in a closely watched study, dealing a blow ...
In a consequential week for Novartis, the Swiss drug maker released results for two of three trials that Wall Street has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results